Aprea Therapeutics
APRE
23 hedge funds and large institutions have $3.07M invested in Aprea Therapeutics in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 4 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
2.69% less ownership
Funds ownership: 35.51% → 32.82% (-2.7%)
12% less funds holding
Funds holding: 26 → 23 (-3)
19% less capital invested
Capital invested by funds: $3.78M → $3.07M (-$711K)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$52K |
| 2 |
SCM
Sio Capital Management
New York
|
+$4.71K |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$2.93K |
| 4 |
LPL Financial
San Diego,
California
|
+$1.71K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$854 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$61.4K |
| 2 |
EAM
Exome Asset Management
New York
|
-$59.1K |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$14.4K |
| 4 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$11.8K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$3.73K |
APRE Hedge Fund Activity: Q2 2025 in Review
23 of the 7,598 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q2 2025, worth a combined $3.07M — down 19% from $3.78M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of APRE and 1 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 7 added.
The largest buyer was Morgan Stanley, adding an estimated $52K. The largest seller was Citadel Advisors, exiting entirely with an estimated $61.4K sold.
- 23 institutional investors held Aprea Therapeutics (APRE) as of Q2 2025, down from 26 in Q1 2025.
- Funds reported $3.07M of Aprea Therapeutics stock for Q2 2025, down 19% quarter-over-quarter.
- 1 fund opened new Aprea Therapeutics positions in Q2 2025 and 4 closed out, a net change of -3 holders.
- The largest Aprea Therapeutics buyer in Q2 2025 was Morgan Stanley, an estimated $52K added.
- The largest Aprea Therapeutics seller in Q2 2025 was Citadel Advisors, an estimated $61.4K sold.
Based on aggregated 13F filings for Q2 2025.